One of CBM2’s faculty members, Prof. Andrew Godwin, has been spending time this spring participating in COVID-19 testing in the Kansas City area. Dr. Godwin, deputy director of the KU Cancer Center and professor and director of molecular oncology in the department of pathology and laboratory medicine at the KU Medical Center, conducted tests in his lab as part of a registry offered to clinical trial patients at the KU Cancer Center. The registry tracked COVID-19 test results and the cancer-treatment timeline of patients testing positive for COVID-19. The tests were paid for by the cancer center’s research budget.
To read more about the registry, visit http://www.kumc.edu/news-listing-page/cancer_center_covid_testing.html